Potentia Pharmaceuticals licenses complement pathway inhibitor for macular degeneration
Potentia Pharmaceuticals, a speciality biotechnology company focused on treatments for AMD, have announced a licensing and share purchase option agreement with Alcon, Inc (ACL:NYSE). The… Read More »Potentia Pharmaceuticals licenses complement pathway inhibitor for macular degeneration